NanoViricides Secures $3.8 Million in Registered Direct Offering

NanoViricides, Inc. has announced a securities purchase agreement with a prominent institutional investor, leading to the purchase of 2,516,339 shares of common stock, along with warrants for the same number of shares. This transaction, valued at approximately $3.8 million, involves a registered direct offering. Each warrant, which will expire in five and a half years, has an exercise price set at $1.75 per share.

D. Boral Capital LLC will manage the placement for this offering. The closing is expected by July 27, 2026, pending standard closing conditions. The offering is conducted via a shelf registration statement approved by the SEC on June 15, 2026. Documents pertaining to the offering will be available online once filed.